CareDx Q3 revenue beats estimates on testing services growth; raises FY2026 outlook
Overview
U.S. precision diagnostics firm's Q3 revenue rose 39%, beating analyst expectations
Q3 adjusted EBITDA nearly doubled yr/yr to $30 mln
Company raised 2026 revenue and adjusted EBITDA guidance
Outlook
CareDx raises 2026 revenue guidance to $520 mln-$530 mln
Company now expects 2026 adjusted EBITDA of $90 mln-$100 mln
CareDx plans a Q1 2027 commercial launch of AlloHeme and broader HistoMap Kidney availability in 2027
Result Drivers
TESTING SERVICES - Revenue rose 65% to $119 mln, including $12 mln from Specialty Oncology and $15 mln of prior-period revenue
PHARMACY SERVICES - Patient and Digital Solutions revenue rose 31%, mainly due to growth in CareDx Pharmacy services
NAVERIS ACQUISITION - Specialty Oncology contributed $12 mln to Testing Services revenue following the acquisition of Naveris
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $139 mln | $120.61 mln (7 Analysts) |
Q3 Net Income | $19 mln | ||
Q3 Adjusted EBITDA | $30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CareDx, Inc. is $61.00, about 15.4% below its October 28 closing price of $72.13
The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 30 three months ago
Reuters Recommended Reads
Oct 29 - Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand
Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)